SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) (USD $)	12 Months Ended							1 Months Ended	3 Months Ended		12 Months Ended				12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Aug. 13, 2012	Dec. 06, 2011	Nov. 10, 2010	Apr. 19, 2010	Jan. 31, 2009 CLP Agreement Genzyme Corporation	Sep. 30, 2010 CLP Agreement Genzyme Corporation	Mar. 31, 2010 CLP Agreement Genzyme Corporation	Dec. 31, 2012 CLP Agreement Genzyme Corporation	Dec. 31, 2011 CLP Agreement Genzyme Corporation	Dec. 31, 2010 CLP Agreement Genzyme Corporation	Jan. 27, 2009 CLP Agreement Genzyme Corporation	Dec. 31, 2010 License Agreement LabCorp
License fees
Amount received			$ 1,896,000					$ 16,650,000	$ 934,250	$ 962,000					$ 4,700,000
Total agreed consideration amount								18,500,000
Amount subject to holdback								1,850,000
Initial collaboration period (in years)								5 years
Sale of common stock (in shares)	63,909,800	56,624,763												3,000,000
Price at which share of common stock are sold (in dollars per share)														$ 2.00
Premium above closing price of common stock at which shares are sold (in dollars per share)														$ 0.51
Closing price of common stock (in dollars per share)	$ 10.59			$ 9.75	$ 8.00	$ 6.00	$ 4.50							$ 1.49
Aggregate premium received over the closing price of common stock														1,530,000
License fee revenue	4,144,000	4,143,000	5,318,000								4,100,000	4,100,000	4,000,000
Product royalty fees		20,000	26,000
Other Income
Cash grant under the Qualifying Therapeutic Discovery Project program administered under Section 48D of the Internal Revenue Code			244,000
Advertising Costs
Advertising expense	$ 57,400	$ 110,000	$ 68,100